Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227185 | 0.91 | S1PR1 (0.48) | S1PR1S1PR3KDM4EMEN1MAPT | |
| SCHEMBL13424962 | 0.87 | S1PR1 (0.49) | S1PR1S1PR3KDM4EMEN1NPC1 | |
| SCHEMBL3212083 | 0.80 | S1PR1 (0.50) | S1PR1S1PR3KDM4EMEN1MAPT | |
| SCHEMBL3218653 | 0.80 | S1PR1 (0.50) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL1424823 | 0.74 | S1PR1 (0.51) | S1PR1S1PR3NPC1RAB9AS1PR5 | |
| SCHEMBL3732206 | 0.73 | S1PR1 (0.51) | S1PR1S1PR3KDM4EMEN1MAPT | |
| SCHEMBL3208492 | 0.72 | S1PR1 (0.51) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL3210670 | 0.71 | S1PR1 (0.58) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL14272872 | 0.71 | ALDH1A1 (0.34) | KMT2A | |
| SCHEMBL3223686 | 0.71 | S1PR1 (0.47) | S1PR1S1PR3S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | S1PR1 96/4885S1PR3 102/4885KDM4E 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.